S2腺苷蛋氨酸对重度妊娠期肝内胆汁淤积症的疗效

Efficacy of S2 SAM on severe intrahepatic cholestasis of pregnancy

目的探讨S2腺苷蛋氨酸对重度妊娠期肝内胆汁淤积症(ICP)的疗效及对围生儿结局的影响。方法将69例重度ICP患者分为治疗组(33例)和对照组(36例)。治疗组用S2腺苷蛋氨酸治疗。比较两组皮肤瘙痒症状、总胆红素(TB)、谷丙转氨酶(ALT)、CG和围生儿结局的差异。结果治疗组TB、ALT、CG,分别由治疗前的(18.45±20.14)μmol/L(、166.40±166.59)U/L、(42.33±23.93)mg/L,下降为治疗后的(11.62±8.86)μmol/L(、47.78±39.47)U/L(、16.13±10.63)mg/L(P<0.05)。治疗组治疗后的ALT、CG值明显降低于对照组(95.50±97.89)U/L,(32.66±28.65)mg/L(P<0.05);治疗组早产率、新生儿窒息率、围生儿病死率低于对照组(P<0.05)。结论 S2腺苷蛋氨酸对ICP疗效可靠,安全性良好。

Objective To observe the efficacy of S-adenosyl-methionin（SAMe） on severe intrahepatic cholestasis of pregnancy（ICP）.Methods Sixty-nine severe ICP patients were divided into two groups of treatment（group A,33 cases） and control（group B,36 cases）.The patients in group A were treated with SAMe.Total bilirubin（TB）,alanine transaminase（ALT）,cholyglycine（CG） and differences of perinatal outcomes were compared.Results TB,ALT and CG before treatment were（18.45±20.14）mol/L,（166.40±166.59）U/L and（42.33±23.93）mg/L,which were significantly higher than（11.62±8.86）mol/L,（47.78±39.47）U/L and（16.13±10.63）mg/L after treatment（P0.05）.After treatment,ALT and CG of group A were significantly lower than （95.50±97.89）U/L and（32.66±28.65）mg/L of group B（P0.05）.The rates of preterm birth,neonatal asphyxia and perinatal infants mortality were less in group A than those in group B（P0.05）.ConclusionSAMe is effective and safe in the treatment of severe ICP with improved perinatal outcomes.